Andrew Dunn

"Some employees who showed up to work at the FDA’s main White Oak campus on Tuesday found out they had been fired when they attempted to check in at security, only to find out that their badges no longer worked and their jobs were gone." https://t.co/0ULtgkRidL

NEW: Google’s bet on AI in drug discovery just got a lot bigger. My latest with @ky_lahucik on Isomorphic's $600 million round — the largest in biotech so far in 2025: https://t.co/7Hke5HahJT

The bizarre legal fight between Alcon and Aurion has taken its next turn Alcon says it now has a majority stake in the cell therapy startup, and has replaced CEO and founder Greg Kunst, effective immediately My latest @endpts: https://t.co/AFzjDRn3YN

RT @pranamanam: Check out my Slack chat with @AndrewE_Dunn @endpts!! 🔥 Please excuse my 🌶️ takes, but definitely got a lot of my thoughts o…

NEW: The Slack chat is back with @pranamanam We dove into the AI bio debate of protein structures vs. sequences ... or what I'd sum up as the pretty picture fallacy https://t.co/j7ATm1AHLD

A big congrats to colleagues across the @endpts newsroom today — we were named finalists for 3 Neal awards: best in industry coverage, newsletter, and generative AI coverage: https://t.co/rbb9N7bmip

RT @endpts: Exclusive from @AndrewE_Dunn: VantAI, a Roivant Sciences spinout, says it's created the first AI model that can predict biomole…

“It tackles the big next step after AlphaFold 3,” Luca Naef, VantAI’s chief technology officer, told me. I talked with @zwcarpenter, @NaefLuca, and @mmbronstein on VantAI's most substantive update since its 2019 start My exclusive for @endpts on Neo-1: https://t.co/6KTRXg3vGY

RT @endpts: Exclusive: CDC's vaccine advisory meeting, delayed earlier this year, is rescheduled for next month, @maxonwifi reports https:/…

Ryan has assembled fantastic panels on what's next for CRISPR & the future of a buzzy area in biology: cell atlases and spatial biology Don't miss it — next Wednesday. Virtually register for free in <30 seconds to get your seat now: https://t.co/wZ7wSpRNgl

Ryan Cross the Science Boss @RLCscienceboss

Join me Wednesday, March 26 for @endpts inaugural science-focused event, Endpoints Catalysts, where I'll be interviewing leaders in CRISPR gene editing, cell atlases + spatial biology, and regenerative medicine. https://t.co/1Ra7NYiLn0

“A great molecule trumps everything,” Anderson said. “The molecule makes the franchise, not the other way around.” If you missed it, I dove into CEO Bill Anderson's plan to save Bayer: https://t.co/ONVdFQqLi2

NEW: Bill Anderson left Roche in 2023 to take one of the most difficult jobs in the corporate world — the CEO of Bayer I recently sat down with Anderson to see how it's going. Here's my latest deep dive into a big question: Can he save Bayer? https://t.co/ONVdFQqLi2

“At this early point, these studies are looking very good, and we’re enthusiastic about that and eager to pour fuel on the fire,” CEO Roger Perlmutter told me. My latest for @endpts on Eikon raising a $351M Series D round: https://t.co/jXajzPpgTl

NEW: Deerfield sued Alcon on Monday Claiming the ophthalmology giant is trying to upend Aurion's IPO plans with a scheme it's calling a "Valentine's Day massacre" in a new lawsuit. A lot to unpack here in the ongoing Aurion-Alcon legal drama: https://t.co/j2PZmYI5pB

My latest dispatch for Post-Hoc, from spending part of last week in DC. The key question: Where is the Roy Vagelos or Ken Frazier of the pharma industry today? https://t.co/5UseMAmm8B

RT @ArmstrongDrew: "Where is the Vagelos or Frazier of today?" @AndrewE_Dunn looks back on last week's pharma-Trump summit, and asks the i…

NEW: Achira, a startup combining AI- and physics-based methods for drug discovery, launched Friday with a $33 million seed round I talked with co-founders @jchodera, @Tkaraletsos, and @zavaindar on their venture: https://t.co/hDjaNKzeql